Novartis chief executive Vas Narasimhan has expressed confidence in the long-term commercial prospects of the company’s injectable cholesterol-lowering treatment, Leqvio.
His comments come in direct response to the recent regulatory approval of Lipfendra, an oral PCSK9 inhibitor developed by Merck and Co.
Lipfendra’s arrival marks the first time patients and physicians have had an oral option within the PCSK9 inhibitor class of cholesterol-lowering medicines.
PCSK9 inhibitors work by blocking a protein that reduces the liver’s ability to remove low-density lipoprotein, commonly known as bad cholesterol, from the bloodstream.
The class has long been seen as a significant advance over traditional statins, particularly for patients who cannot tolerate statins or who require more aggressive lipid management.
Leqvio, which is administered by injection twice a year, has been positioned by Novartis as a convenient and highly effective option for patients managing elevated cholesterol levels.
Narasimhan remains unfazed by the competitive threat posed by Merck’s newly approved oral alternative, doubling down on his conviction in Leqvio’s differentiated profile.
The twice-yearly injection schedule is seen by many clinicians as a meaningful adherence advantage, reducing the burden of daily pill-taking that affects compliance across cardiovascular therapies.
Novartis has invested heavily in building out the commercial infrastructure necessary to drive adoption of Leqvio among cardiologists and primary care physicians across key markets.
The cholesterol treatment market represents a substantial commercial opportunity, given that elevated LDL cholesterol remains one of the leading modifiable risk factors for cardiovascular disease globally.
Competition between injectable and oral formulations within the same drug class is not unprecedented, and outcomes data and physician familiarity often play a decisive role in market dynamics over time.
Novartis shares trade on the New York Stock Exchange under the ticker NVS, while Merck trades under MRK, and investors in both companies will be watching the evolving competitive landscape closely.